Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Polycystic Ovary Syndrome 2Neoplasms 2Urinary Bladder Neoplasms 1Stage I Prostate Adenocarcinoma 1Prostatic Neoplasms 1Osteoporosis 1Infertility 1Esophageal Neoplasms 1Endometrial Neoplasms 1Diarrhea 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Brain Neoplasms 1Anovulation 1Adenocarcinoma 1

Interventions

Exercise 4Cholecalciferol 4Aspirin 4Nutrition Assessment 3Gonadotropin-Releasing Hormone 3Blood Pressure 3Atorvastatin 3palbociclib 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2acalabrutinib 2Vitamin E 2Vitamin D 2Social Determinants of Health 2Rosuvastatin Calcium 2Methods 2Metformin 2Geritol 2Fish Oils 2Fatty Acids, Omega-3 2Ethanol 2Electrocardiography 2Educational Status 2Echocardiography 2Diet, Mediterranean 2Blood Specimen Collection 2Antineoplastic Agents 2Absorptiometry, Photon 2zanubrutinib 1xinmailong 1sofosbuvir-velpatasvir drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cardiovascular Diseases × Raloxifene Hydrochloride × Clear all
NCT00190593 2007-01-26

Raloxifene Use for The Heart

Eli Lilly and Company

Phase 3 Completed
10,000 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡